QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Price, News & Analysis

$27.71
+0.69 (+2.55%)
(As of 03:29 PM ET)
Today's Range
$26.61
$28.23
50-Day Range
$23.82
$32.80
52-Week Range
$22.67
$47.48
Volume
656,858 shs
Average Volume
1.57 million shs
Market Capitalization
$2.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.86

Intellia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
150.6% Upside
$67.86 Price Target
Short Interest
Bearish
14.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.78mentions of Intellia Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.04 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.58) to ($5.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

150th out of 939 stocks

Diagnostic Substances Industry

3rd out of 13 stocks

NTLA stock logo

About Intellia Therapeutics Stock (NASDAQ:NTLA)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Stock Price History

NTLA Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Intellia Therapeutics Is On The Move
Intellia Therapeutics just downgraded at Goldman Sachs, here's why
Q4 2023 Intellia Therapeutics Inc Earnings Call
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
526
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$67.86
High Stock Price Target
$107.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+154.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$-481,190,000.00
Net Margins
-893.34%
Pretax Margin
-1,326.51%

Debt

Sales & Book Value

Annual Sales
$36.28 million
Book Value
$11.73 per share

Miscellaneous

Free Float
93,223,000
Market Cap
$2.57 billion
Optionable
Optionable
Beta
1.80
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. John M. Leonard M.D. (Age 67)
    President, CEO & Director
    Comp: $1.06M
  • Mr. Glenn G. Goddard CPAMr. Glenn G. Goddard CPA (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $630.91k
  • Dr. Laura Sepp-Lorenzino Ph.D. (Age 63)
    Executive VP & Chief Scientific Officer
    Comp: $670.58k
  • Mr. James E. Basta Esq. (Age 58)
    J.D., Executive VP, General Counsel & Corporate Secretary
    Comp: $616.15k
  • Dr. David Lebwohl M.D. (Age 69)
    Executive VP & Chief Medical Officer
    Comp: $671.42k
  • Mr. Derek Hicks (Age 51)
    Executive VP & Chief Business Officer
    Comp: $823.42k
  • Mr. Nessan Bermingham Ph.D. (Age 51)
    Founder & Member of Scientific Advisor Board
    Comp: $1.38M
  • Dr. Rachel E. Haurwitz Ph.D. (Age 38)
    Co-Founder
  • Dr. Andrew May Ph.D.
    Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna Ph.D. (Age 59)
    Founder & Member of Scientific Advisor Board

NTLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price target for 2024?

14 Wall Street analysts have issued 1 year price objectives for Intellia Therapeutics' stock. Their NTLA share price targets range from $29.00 to $107.00. On average, they predict the company's share price to reach $67.86 in the next twelve months. This suggests a possible upside of 150.6% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2024?

Intellia Therapeutics' stock was trading at $30.49 at the beginning of the year. Since then, NTLA stock has decreased by 11.2% and is now trading at $27.08.
View the best growth stocks for 2024 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, February, 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. The firm earned ($1.92) million during the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 43.91% and a negative net margin of 893.34%. During the same quarter in the previous year, the company earned ($1.40) earnings per share.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.74%), Vanguard Group Inc. (9.32%), Vanguard Group Inc. (8.69%), Sumitomo Mitsui Trust Holdings Inc. (3.88%), Nikko Asset Management Americas Inc. (3.88%) and Wellington Management Group LLP (2.56%). Insiders that own company stock include Caroline Dorsa, David Lebwohl, Eliana Clark, Glenn Goddard, James Basta, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTLA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners